Core Viewpoint - The stock of Basilea Pharmaceutica (02616) has seen a significant increase, with a rise of over 9% and a current price of 10.35 HKD, driven by recent investment activities and positive clinical trial developments [1] Group 1: Investment Activity - Singapore's Government Investment Corporation (GIC Private Limited) has increased its stake in Basilea Pharmaceutica by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD [1] - Following this acquisition, GIC's ownership in Basilea has risen from 0.00% to 5.49% [1] Group 2: Clinical Development - Basilea's core product, the second-generation IO product CS2009, is currently undergoing global multi-center Phase I/II clinical trials in Australia and China, with plans to expand to the U.S. for Phase II enrollment [1] - The company anticipates that the number of patients enrolled will exceed 100 by the end of the year, with plans to initiate Phase Ib/II dose expansion and registration studies in the second half of 2025 [1] - Data from the Phase I clinical study, including safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity, is expected to be presented at the ESMO conference in October 2025, generating significant interest [1] Group 3: Future Outlook - Given the potential for product launches and a robust clinical development pipeline, the future growth prospects for Basilea are considered promising [1]
港股异动 | 基石药业-B(02616)再涨超9% GIC斥资超6亿港元增持公司股份 二代IO产品即将披露数据